We are live on ! Find out more
VRNA

Verona Pharma
VRNA

Delisted

VRNA was delisted on the 6th of October, 2025.

Back to rankings

17 hedge funds and large institutions have $70.1M invested in Verona Pharma in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

13% more funds holding

Funds holding: 15 → 17 (+2)

0.15% more ownership

Funds ownership: 7% → 7.15% (+0.15%)

24% less capital invested

Capital invested by funds: $92.3M → $70.1M (-$22.1M)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
17
Holders Change
+2
Holders Change %
+13.33%
% of All Funds
0.38%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
3
Increased
1
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WS
Wedbush Securities
California
+$160K
2
TRCT
Tower Research Capital (TRC)
New York
+$2.12K
3
UBS Group
UBS Group
Switzerland
+$1.57K

Top Sellers

Rank Fund Capital Flow
1
FCMI
Foresite Capital Management III
California
-$3.34M
2
FCMI
Foresite Capital Management IV
California
-$104K
3
Deutsche Bank
Deutsche Bank
Germany
-$2.76K

VRNA Hedge Fund Activity: Q4 2018 in Review

17 of the 4,496 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q4 2018, worth a combined $70.1M — down 24% from $92.3M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new VRNA positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Wedbush Securities, opening a new position worth an estimated $160K. The largest seller was Foresite Capital Management III, cutting an estimated $3.34M.

  • 17 institutional investors held Verona Pharma (VRNA) as of Q4 2018, up from 15 in Q3 2018.
  • Funds reported $70.1M of Verona Pharma stock for Q4 2018, down 24% quarter-over-quarter.
  • 3 funds opened new Verona Pharma positions in Q4 2018 and 1 closed out, a net change of +2 holders.
  • The largest Verona Pharma buyer in Q4 2018 was Wedbush Securities, an estimated $160K added.
  • The largest Verona Pharma seller in Q4 2018 was Foresite Capital Management III, an estimated $3.34M sold.

Based on aggregated 13F filings for Q4 2018.